Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded by Leerink Partners to “Strong-Buy” Rating

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by stock analysts at Leerink Partners to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

Other analysts have also issued reports about the stock. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday. JPMorgan Chase & Co. reissued an “overweight” rating and set a $22.00 target price on shares of Amneal Pharmaceuticals in a research note on Wednesday, August 26th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. Finally, UBS Group lifted their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $19.57.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $17.25 on Wednesday. The stock has a market capitalization of $5.51 billion, a price-to-earnings ratio of 35.20 and a beta of 1.24. The company’s 50-day simple moving average is $17.77 and its 200-day simple moving average is $15.01. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. Amneal Pharmaceuticals has a one year low of $9.49 and a one year high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities analysts anticipate that Amneal Pharmaceuticals will post 0.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Nikita Shah sold 146,403 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jason B. Daly sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 413,016 shares of company stock valued at $7,216,567. Insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. California State Teachers Retirement System lifted its stake in shares of Amneal Pharmaceuticals by 1,592.8% during the second quarter. California State Teachers Retirement System now owns 3,508,079 shares of the company’s stock valued at $60,725,000 after acquiring an additional 3,300,840 shares during the period. Westshore Wealth LLC bought a new position in Amneal Pharmaceuticals in the third quarter valued at about $13,833,000. Morgan Stanley increased its position in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares during the period. Allspring Global Investments Holdings LLC increased its position in Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after purchasing an additional 1,069,400 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Amneal Pharmaceuticals during the 2nd quarter worth about $17,573,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.